EUCTR2009-014816-37-IT
Active, not recruiting
Not Applicable
Open prospective, uncontrolled pilot study to assess the tolerability and efficacy of Lymdiaral injektopas (Pascoe-Named) in the treatment of pannicolopatia-edema-fibrosclerotic (PEFS) and venous-lymphatic insufficiency chronic (IVLC)through technical intradermotherapy District (ITD) - tolerability and efficacy of Lymdiaral injektopas
AMED SR0 sitesNovember 5, 2009
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- tolerability and efficacy of Lymdiaral Injektopas (Pascoe-Named)
- Sponsor
- AMED SR
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Age\> 18 years \-Suffering from IVLC connected to PEFS
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Will be excluded from the study subjects who also have one of the following signs or symptoms or conditions: \- Secondary Edema to other diseases (disendocrinopatie, kidney disease, liver disease, connective, heart disease). \- Patients suffering from incontinence of hemodynamic precludes saphenous\-femoral \- Pharmacological treatments in progress that may change the evaluation of results (corticosteroids, estrogen\-progestine, Ca\-antagonists phlebotonic, diuretics). \- History pathological autoimmune disorders, neoplastic and paraneoplastic syndromes. \- History pathological positive for allergy to medications in general. \- Hypersensitivity to one or more components of the product concerned and the composite. \-Pharmacological treatments in progress that may change the evaluation of results (corticosteroids, estrogen\-progestine, Ca\-antagonists, phlebotonic, diuretics) \- In Combination with other methods for the same pathology. \- Pregnancy \- Breastfeeding \- In diet therapy treatment \- Participation in other clinical studies during the previous six months \- Conditions that in the opinion of the physician evaluator, interfere with the ongoing study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasiaNL-OMON48255Sint Antonius Ziekenhuis20
Active, not recruiting
Phase 1
Tacrolimus for bleeding in hereditary hemorrhagic telangiectasia patientsEUCTR2019-003585-40-NLSt. Antonius Hospital20
Not yet recruiting
Not Applicable
A prospective study to assess the effect of adalimumab on cardiovascular biomarkers in participants with severe chronic plaque psoriasisChronic plaque psoriasisSkin - Dermatological conditionsInflammatory and Immune System - Other inflammatory or immune system disordersACTRN12613000419763Dr Anna Braue15
Active, not recruiting
Not Applicable
An open label, randomized pilot study to evaluate diagnostic treatment interruption in HIV-positive children under a stable antiretroviral therapy in order to save medication and reduce possible side effects.B24Unspecified human immunodeficiency virus [HIV] diseaseDRKS00000473J.W. Goethe UniversitätZentrum für Kinder- und Jugendmedizin1
Recruiting
Phase 2
Study to evaluate the efficacy of Sucralfate as a healing agent in bed sores.CTRI/2016/03/006745Internal FLUID Grant Christian Medical College Vellore30